H.C. Wainwright lowered the firm’s price target on Lexeo Therapeutics to $21 from $22 and keeps a Buy rating on the shares following the Q2 report. The firm cites share count increases for the target drop.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
- Lexeo Therapeutics participates in a conference call with JPMorgan
- Lexeo Therapeutics reports ‘positive’ results from LX2006 study
- Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
- Lexeo Therapeutics to report interim Phase 1/2 clinical data of LX2006